Richard Haas
Neurology with Special Qualifications in Child Neurology · San Diego, CANPI 1700801867
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,630 of the $26,564 with a category attached, or 85.2%. 19 manufacturers reported payments, led by UCB SA at 54.5% of the total. 2025 is the largest year on record at $12,267, 4.0 times the $3,029 reported in 2019.
Across 109 payments — averaging $243.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$14K
- Greenwich Biosciences, Inc.$4K
- UCB, Inc.$3K
- GW Research Limited$2K
- PTC Therapeutics, Inc.$2K
- Sunovion Pharmaceuticals Inc.$836
- plus $630 from 13 others
Across 184 payments — averaging $6168.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$484K
- Astellas Pharma Inc$208K
- PTC Therapeutics, Inc.$170K
- Sarepta Therapeutics, Inc.$162K
- UCB Biosciences Inc.$82K
- GW Research Limited$18K
- plus $13K from 1 others
What the payments were for
- Consulting fees$22,63085%
- Travel & lodging$1,6346%
- Food & beverage$2,2809%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 5 | $14,487 |
| Greenwich Biosciences, Inc. | 4 | $3,905 |
| UCB, Inc. | 5 | $2,868 |
| GW Research Limited | 6 | $2,019 |
| PTC Therapeutics, Inc. | 2 | $1,819 |
| Sunovion Pharmaceuticals Inc. | 57 | $836 |
| Mallinckrodt Enterprises LLC | 9 | $195 |
| Aquestive Therapeutics, Inc. | 5 | $105 |
| Eisai Inc. | 3 | $63 |
| Mallinckrodt Hospital Products Inc. | 2 | $50 |
| Novartis | 2 | $36 |
| CSL Behring | 2 | $33 |
| SK Life Science, Inc. | 1 | $27 |
| Neurelis, Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Catalyst Pharmaceuticals, Inc. | 1 | $20 |
| Upsher-smith Laboratories LLC | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fintepla$125
How this compares
$26,564 in reported general payments places this provider in the 85th percentile of 216 neurology with special qualifications in child neurology providers in California.
See all neurology with special qualifications in child neurology providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 16 | $537 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in San Diego
- Brittany PassiakSan Diego$90K
- Joseph GleesonSan Diego$69K
- John CrawfordSan Diego$27K
- Shifteh SattarSan Diego$21K
- Jennifer YangSan Diego$15K
- Doris TraunerSan Diego$15K
- Olivia Kim McManusSan Diego$11K
- Katherine LongardnerSan Diego$11K
- Aliya FrederickSan Diego$7K
- Michael ChezSacramento$374K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.